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 Introduction
　Numerous studies have demonstrated that some 
viruses and bacteria including mycoplasmas could be 
related to the pathogenesis of arthritis1―3.  Mycoplasma 
species have been incriminated as causative agents of 
arthritis since they were found in rats and mice with 
natural arthritis4.  Williams et al. reported the presence 
of Mycoplasma fermentans（M. fermentans）in the SF 
of patients with rheumatoid arthritis（RA） , but these 
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results could not be reproduced in further investiga-
tions probably because of the fastidious growth 
requirements of the microorganism5.  Recently, mole- 
cular biology tools have enabled us to detect and isolate 
M. fermentans in joints of patients with RA and other 
joint disorders,  and the results suggest that M. 
fermentans may play a role in the development of joint 
disease6，7.
　Some mycoplasmas may act as nonspecific mitogens 
of B and T cells, by producing superantigen8.  Recent 
studies have shown the presence of M. fermentans DNA 
and specific antibodies to the bacteria in the SF of 
patients with RA9.  M. fermentans possesses a potent 
immunomodulator product named macrophage activat-
ing lipopeptide 2（MALP-2）which activates macrophage 
to release various proinflammatory cytokines  which 
may in turn increase the neutrophilic infiltrate into the 
joints10.  We have found that M. fermentans derived 
lipoprotein can induce the production of cytokines 
（TNF- α and IL-1）and matrix degrading enzyme 
through interaction with its receptor, Toll like receptor
（TLR）-211.
　Mycoplasmas are common inhabitants of the human 
respiratory and genitourinary tracts where they pro- 
duce chronic infections, and they are able to invade 
other tissues and in some cases induce autoimmune 
responses12.  The pathogenesis of some human myco- 
plasmal infections in the joints is poorly understood. 
Even though this microorganism has been isolated in 
the joints, it is not clear how the bacteria enter the body 
and how they reach the joints.  Antonio et al. 
experimentally reproduced the arthritogenic ability of 
M. fermentans isolated from the human respiratory 
tract by injecting them into the trachea13.  They found 
that live organisms settled down in the joints and 
induced arthritis.  These observations will shed light on 
the role of M. fermentans and/or its antigen in arthritis.
　In this study, we evaluated whether infection with M. 
fermentans is associated with internal derangement
（ID）and osteoarthritis（OA）of the temporomandibular 
joint（TMJ） .  We also describe our results regarding the 
detection of DNA derived from M. fermentans and the 
specific immunoreactivity of the patient SF and sera 
against mycoplasmal antigen.
 
Materials and Methods
1．Samples
　We studied 115 TMD patients including 81 ID and 34 
OA patients.  All patients gave informed consent before 
the study commenced.  Sera from some TMD patients 
as well as craniomaxillofacial diseases other than TMD 
were also subjected to the experiments.  All synovial 
fluid samples were collected at Yamagata University, 
with which Dr. Shibata was formerly affiliated.  Study 
approval was obtained from the Ethics Committee of 
the Medical Faculty, Yamagata University, Yamagata. 
The average age of the patients was 37 years old（range 
14-70 years） .  The patients were screened for M. 
fermentans infection by detection of its DNA and by 
determination of antibody response to M. fermentans in 
SF and sera.  SF was collected by puncture with a 23-
gauge needle into the superior joint space from an 
infero-lateral approach.  By directly aspirating the SF, 
we could obtain 0.2 - 0.5 ml of undiluted SF from 
the TMJ.  All samples were stored at － 30℃ until 
processing.
2．Bacterial Strain and Culture Condition
　M. fermentans, strain PG18, was obtained from 
American Type Culture Collection（Rockville, MD, 
USA） . It was grown in PPLO broth（Difco Laboratories, 
Detroit, MI, USA）supplemented with 20％（v/v）horse 
serum（GIBCO Life Technologies, Inc., Grand Island, 
NY, USA） , 10％（w/v）yeast extract（Difco） , 1％（w/v）
D-glucose, 0.002％（w/v）phenol red, and penicillin G
（1,000U/ml） 14.  Cultures were incubated at 37℃ for 48 
h under anaerobic condition.  The cells were harvested 
by centrifuging the cultures at 15,000 × g for 15 min, 
washed three times with sterile PBS, and suspended in 
sterilized water.
3．Preparation of samples for PCR
　SF samples（200  μ l）were mixed with 800  μ l of HMW 
buffer and incubated at 50℃ for 2 h15.  The DNA was 
extracted twice with an equal volume of phenol 
saturated with TE buffer（10 mM Tris-HCl（pH 7.5） 
containing 1 mM EDTA） , and was also extracted once 
with phenol-chloroform-isoamyl alcohol（24:1, v/v） . 
Sodium acetate（0.3 M）was added to the aqueous phase, 
and the DNA was precipitated with two volumes of 
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absolute ethanol.  The precipitate was suspended in TE 
buffer. 
4．PCR assay
　PCR amplification was performed essentially as 
described previously in a total volume of 20 μ l PCR 
solution buffer16.  Primers for β-actin（5’-TGA CGG 
GGT CAC CCA CAC TGT GCC-3’ and 5’-TAG AAG CAT 
TTG CGG TGG ACG ATG-3’）and for M. fermentans
（RW004 : 5’-GGA CTA TTG TCT AAA CAA TTT CCC-3’ 
and RW005 : 5’-GGT TAT TCG ATT TCT AAA TCG CCT-
3’）were used for the amplification17.  The PCR 
amplification reaction utilized 1 μ g of DNA derived from 
SF extract, 10× PCR buffer（100 mM Tris-HCl pH 8.3, 
500 mM KCl, 25 mM MgCl2） , 2.5 mM dNTPs, 3’
（antisense）primer, 5’（sense）primer, and 2.5 units of 
Taq DNA polymerase（Takara Bio. Inc., Shiga, Japan） . 
As a positive control, DNA from M. fermentans strain 
PG18 was used for amplification in each experiment. 
PCR was carried out in a PCR thermal cycler（Takara）
with the following temperature profile : denaturation at 
94℃ for 2 min, primer annealing at 60℃ for 30 sec in 
β-actin and at 56℃ for 30 sec in M. fermentans, 
and polymerization at 72℃ for 1 min in each cycle. 
Amplification was carried out at 30 cycles in β -actin 
and 45 cycles in M. fermentans.  Amplification products 
were visualized under ultraviolet light after electro- 
phoresis by 1.5％ agarose gel（Wako Pure Chemical 
Industries, Osaka, Japan）followed by staining with 
ethidium bromide.
5．Preparation of M. fermentans lipoproteins by 
Triton X-114 phase separation
　Mycoplasma membrane lipoproteins were prepared 
by the phase-partitioning method using a detergent, 
Triton X-114, extraction as described previously18. 
Briefly, after light sonication, M. fermentans cells were 
suspended in sterilized water. The cell suspension was 
mixed with 20％ Triton X-114 working solution and TS 
buffer（10 mM Tris-HCl（pH 7.4） , 154 mM NaCl） .  The 
tube containing the mixture was placed on a rotor at 
4℃ for 60 min, and then it was centrifuged at 10,000×
g for 4 min at 4℃.  After removal of the aqueous phase, 
the Triton phase was resuspended in TS buffer, and 
incubated for 5 min on ice followed by 37℃ for 5 
min, and then centrifuged at 10,000 × g for 5 min. 
Lipoprotein（TXLP）from the Triton X-114 phase 
was precipitated by adding methanol and used for 
immunoblotting after being suspended in sterile water.
6．Detection of antibody against M. fermentans 
by Western-blot analysis
　TXLP（0.3  μ g）was fractionated by SDS-PAGE on 
12.5％ acrylamide gel and transferred to a nitrocellu-
lose membrane（Amersham Pharmacia Biotech, Buck-
inghamshire, England） .  After being blocked with 
Tween-PBS containing 2.5％ skim milk, the membrane 
was probed with either SF or sera（1.5  μ g protein）by 
means of overnight incubation at 4℃.  After being 
probed, the membrane was washed three times with a 
washing buffer（20 mM Tris-HCl and 500 mM NaCl） . 
Next, it was incubated for 1 h at room temperature with 
peroxidase-conjugated anti-human IgG F（ab’） 2 anti-
body diluted to 1:1000（Cortex Biochem, CA, USA） .  The 
membrane was then washed again in the same manner, 
followed by developing the blots with an enhanced 
chemiluminescence detection system（Amersham Phar-
macia Biotech） .  Mouse hyperimmune antiserum to 
TXLP and rat anti-mouse IgG1 conjugated with 
peroxidase（Nippon Becton Dickinson Company Ltd., 
Tokyo, Japan）was used as a positive control.
7．Statistical analysis
　The statistical significance of differences between 
experimental groups was analyzed by the χ 2 test.  A p 
value of less than 0.05 was considered significant.
Results
1．Detection of M. fermentans in SF
　Characterization of the patients and the percentage 
of SF samples positive for M. fermentans DNA are 
shown in Table 1.  M. fermentans DNA was detected in 
43（37.4％）out of 115 samples from patients with TMD. 
SF samples from 32（39.5％）of 81 patients with ID were 
positive for the DNA.  Also, samples from 11（32.4％） 
of 34 patients with OA were positive for M. fermentans 
DNA.  There was no difference in positive rates of M. 
fermentans DNA between ID and OA.  No difference 
was observed also in the percentage positive for M. 
fermentans DNA between males and females.  Represen- 
tative results of the PCR analyses are shown in Fig. 1. 
In ID patients, however, the positive rate of M. 
fermentans DNA was different between patients aged 
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over 40 years and those of under 40 years.  Thus, the 
detection rate of M. fermentans DNA was found to be 
significantly higher in elderly ID patients than in 
younger ones（Table 2） .  In OA, no differences in 
age were demonstrated between patients positive or 
negative for M. fermentans DNA（Table 2） .
 
2．Detection of Anti-M. fermentans antibody in 
SF and sera
　Verification of the specific IgG antibodies to M. 
fermentans-derived lipoproteins was obtained by West- 
ern-blot analyses.  The use of peroxidase-conjugated 
anti-human IgG F （ab’） 2 antibody instead of using anti-
human whole Ig as secondary antibody enabled us to 
detect more easily M. fermentans specific antibodies in 
SF and sera（data not shown） .  Positive reactivities to 
M. fermentans lipoproteins with different molecular 
sizes（56 kDa, 48 kDa, 38 kDa and 29 kDa）were 
observed in SF samples from TMD patients（Fig. 2 A, 
B） , and designated as p56, p48, p38, and p29, 
respectively.  No difference in reactivities by age（over 
40 or under 40） , sex, and disease categories（ID or OA）
was demonstrated between patients positive and 
negative for M. fermentans DNA（Fig. 2 A and B） .  The 
sera taken from patients with diseases other than TMD 
positively reacted with M. fermentans lipoproteins as 
depicted in Fig. 3.  The sera from TMD patients also 
exhibited similar reactivity to M. fermentans lipopro-
teins irrespective of the disease categories, but 
prominent reactivity to p56, p48, and p29 was 
uniformly observed（Fig. 3） .  The reactivity pattern of 
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Table 1　Characterization of patients and positive rate of M. fermentans DNA in 
SF of TMD patients
M. fermentans DNA positive samples1Total sample tested
Sex
M/F
Mean are
（yr）
No. of
Samples（％）
Sex
M/F
Mean are
（yr）
No. of
samples
Type of TMD
4/28
1/10
5/38
31（15-63）
45（16-67）
38（15-67）
32（39.5％）
11（32.4％）
43（37.4％）
11/70 
 3/31 
14/101
28（14-63）
46（16-70）
37（14-70）
 81
 34
115
ID2
OA3
ID＋ OA
1 M. fermentans DNA was detected by PCR analysis using specific primers reported by 
Watanabe et al.（Ref. 15） . 2 ID : Internal derangement,  3 OA : Osteoarthritis
Table 2　Prevalence of M. fermentans DNA in various 
TMJ arthropathies
No. of SF samples1No. of
patientsAge
2
21（31.8％）6640≧
ID3
1 M. fermentans DNA was detected by PCR analysis using 
specific primers reported by Watanabe et al. 2 SF samples 
were divided into two categories according to the patient’s 
age, under 40 and over 40 years of age. Statistical analyses 
were performed by theχ 2 test. Values significantly different
（P ＜ 0.05）are shown by an asterisk. 3 ID : Internal 
derangement, 4 OA : Osteoarthritis.
＊
＊
Fig. 1　Representative results of the PCR screening assay of the SF from the TMD patients 
targeting 206 bp DNA sequences of M. fermentans. P and N represent positive 
control and negative control, respectively. M. fermentans DNA（206 bp）in the SF 
from 12 representative patients is shown in the upper lane. β -actin DNA was 
positive in all SF samples.
the SF to various M. fermentans lipoproteins was 
absolutely different from that observed in the sera.
3．Differences in the specificity to certain lipo- 
proteins detected in SF and sera of the 
identical patient
　The reactivity pattern of the SF to various M. 
fermentans lipoproteins was absolutely different from 
that observed in the sera.  Among lipoproteins from M. 
fermentans, immunoreactivity to p48 and p29 was 
conspicuously observed both in SF and sera taken from 
the identical patient.  Interestingly, the immunoreactiv-
ity to p56 was much lower in the SF than that in the 
sera, and conversely the relative reactivity to p48 was 
much stronger in the SF than that in the sera（Table 3 
and Fig. 4） .  Similar reactivity patterns of the SF and 
the sera in Western blotting were unequivocally 
observed in other patients.  The relatively high 
reactivity of the SF against p48 and p29 lipoproteins 
suggests local production of IgG antibodies specific for 
p48 and p29 in the TMJ.
Discussion
　We detected M. fermentans DNA in SF of 37.4％ of 
patients with TMD.  Our results are in accordance with 
those of Henry et al., who found M. fermentans DNA in 
a similar percentage in the TMJ posterior bilaminar 
tissue from patients with TMD16.  They also reported 
the isolation of DNAs of several bacterial species from 
TMJ tissue.  Although the primer sequence, RW004 and 
RW005, used to detect M. fermentans which was 
reported by Henry et al. and ourselves involved the 
insertion-like sequence that had been shown to also 
detect M. orale, there was no big difference in the 
positive rate of the DNA between the SF and the 
tissue15.  In contrast, Watanabe et al. detected a much 
higher prevalence of M. fermentans DNA（61％）in SF 
of patients with closed lock symptoms of the TMJ, 
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Fig. 2　Western-blot analysis of TXLP immunoblotted with the SF of TMD patients. Each 
TXLP lysate（0.3 μ g）was fractionated by 12.5％ SDS-PAGE and transferred to a 
nitrocellulose membrane. The membrane was reacted with the SF and then incubated 
with peroxidase-conjugated anti-human IgG F （ab’） 2 Ab diluted to 1:1000. The faintly 
reacted bands were observed at 38 kDa and/or 56 kDa, but the 29 kDa and 48 kDa 
bands could be observed clearly in all samples. As control, immunoblot using mouse 
hyperimmune antiserum against TXLP and anti-mouse IgG1 is shown in column P. 
Samples from ID patients are depicted on panel A, and those from OA patients in panel 
B. Numbers on the left side of the column indicate molecular size in kDa.
Table 3　Reactivity patterns of anti-M. fermentans 
antibodies in SF or sera
Lipoproteins
Sample
29 kDa38 kDa48 kDa56 kDa
＋＋＋
＋＋＋
＋
＋
＋＋ 
＋＋ 2
＋＋＋ 3
＋ 1
Sera
SF　
Intensity of the band in Western blots was evaluated as 
weak, medium, and strong.
compared to that of ours15.  There was no difference 
between PCR-positive and -negative patients regarding 
sex and disease categories of the TMJ（e.g., internal 
derangement or osteoarthritis） .  The presence of M. 
fermentans DNA in SF, however, does not seem to be 
contamination, since we did not detect this DNA 
randomly distributed among patients.  The higher 
incidence of M. fermentans DNA in elderly patients who 
suffered from ID suggests a causal relationship of this 
organism to ID.
　Mycoplasmas, including M. fermentans, are excellent 
candidates for induction of arthritis in humans ; 
M. fermentans can induce experimental arthritis in 
animals, and its cell membrane extracts（lipoproteins） 
are shown to induce the production of various kinds of 
proinflammatory cytokines by human macrophages, 
including TNF- α , IL-1 β and IL-6, which are key 
cytokines in the development of RA as well as other 
arthropathies including TMD15，19，20.  Especially, these 
cytokines are associated with synovitis in ID and 
osteoarthritic changes of the TMJ21，22.  Our previous 
study revealed that M. fermentans-derived membrane 
fraction（TXLP）upregulates TNF- α and IL-1 β produc-
tion from monocytes, and it also stimulates gene 
transcription of matrix metalloproteinase（MMP）-3 in 
rabbit synoviocyte cell line11.  Thus the high prevalence 
of M. fermentans DNA in elderly ID patients may 
explain the possibility that they can induce or 
perpetuate inflammatory reaction in the TMJ.
　Kaufmann et al. recently identified a well-defined 
lipopeptide, named 2-kDa macrophage-activating lipo- 
peptide（MALP-2） , from M. fermentans10.  This lipo- 
peptide with N-terminal cysteine residue bound to a 
diacylated glyceride residue through a thioester linkage 
was reported as a potent activator of mammalian cells. 
Various mycoplasmal lipoproteins have their active site 
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Fig. 4　Western-blot analysis of TXLP immunoblotted 
with the SF and serum of the TMD patients. Each 
TXLP lysate（0.3μ g）was fractionated by 12.5％ 
SDS-PAGE and transferred to a nitrocellulose 
membrane. The membrane was reacted with the 
patient’s SF as well as serum and then incubated 
with peroxidase-conjugated anti-human IgG F
（ab’） 2 diluted to 1:1000. Immunoblots using 
synovial fluid（SF）and serum（Se）from two 
identical patients are depicted in columns No.1 
and No. 2. The control immunoblot using mouse 
hyperimmune antiserum against TXLP and anti-
mouse IgG1 is depicted in column P. Numbers on 
the left side of the column indicate molecular size 
in kDa.
Fig. 3　Western-blot analysis of TXLP immunoblotted 
with the control sera.  Each TXLP lysate（0.3μ g）
was fractionated by 12.5％ SDS-PAGE and 
transferred to a nitrocellulose membrane. The 
membrane was reacted with the serum and 
then incubated with peroxidase-conjugated anti-
human IgG F （ab’） 2 diluted to 1:1000. The control 
immunoblot using mouse hyperimmune anti- 
serum against TXLP and anti-mouse IgG1 is 
depicted in column P. Numbers on the left side of 
the column indicate molecular size in kDa.
on N-terminal moiety, the structure of which is similar 
to MALP-223.  As for the ligands for recognizing the 
lipoproteins and MALP-2, TLRs have been recently 
discovered24.  Among 10 identified TLRs, TLR2 has 
been shown to be essential for the recognition of distinct 
bacterial components, such as peptidoglycan（PGN） , 
lipoarabinomannan（LAM） , and lipoprotein（LP） 25. 
Subsequent to ligand binding, TLR-2 initiates signaling 
that leads to the activation of transcription factor NF- 
κ B, which also initiates the production of reactive 
oxygen species, initiation of the proinflammatory 
cytokines, and upregulation of costimulatory mole-
cules25.  Thus, it is probable that once an inflammatory 
process of the TMJ synovium is somehow induced by 
immune reaction to a certain bacterial antigen or by 
mechanical overloading, inflammatory cytokines will be 
produced with a pattern similar to RA.
　It has been suggested that M. fermentans is found in 
SF due to passive carriage of this organism from other 
organs, which was normally found in the pharynx and 
saliva of 20-40％ as well as in 10％ of peripheral 
mononuclear cells of humans26.  Thus, the presence of 
M. fermentans in SF could be regarded as that of an 
innocent bystander without pathogenic significance. 
However, if this were the case, we would expect to 
detect M. fermentans DNA in SF of all patients 
irrespective of their ages and disease categories（ID 
or OA） .  Furthermore, the high prevalence of M. 
fermentans in aged patients does not support this 
hypothesis.  We believe that Mycoplasma may not be 
permanently present in SF or TMJ tissue and therefore 
might not always be detectable.  In experimental 
arthritis in rabbits by M. arthritidis and in swine by M. 
hyorhinis, Mycoplasma could only be isolated from the 
joints for a few weeks post-infection ; it then dis- 
appeared, while the chronic arthritis process contin-
ued27.  Therefore, we consider the Mycoplasma infection 
in the TMJ is transient but the accumulation of its 
antigen in the TMJ tissue may induce a specific 
humoral immune response against the inspection, and 
the phenomenon may persist for a long time in the body.
　The anti-M. fermentans immunoreactivity patterns to 
the various lipoproteins in the SF were different from 
those of the sera（Fig. 4） .  This phenomenon suggests 
local production of antibodies specific for a certain M. 
fermentans lipoprotein in the joint per se.  This also 
indicates that M. fermentans or its membrane product 
can elicit an immune response inside the joint.  Similar 
findings were reported regarding M. fermentans in RA, 
where the bacterial antigens were detected in the joints, 
and levels of antibodies to the bacteria in the SF were 
higher than those observed in the sera6.  We did not 
measure the level of antibody in the SF by ELISA, but 
the different epitope specificities of anti-M. fermentans 
antibody detected in the SF and the sera strongly 
suggest the joint specific humoral immune response.
　It is possible that Mycoplasma persists at another 
location in the body（e.g., urogenital or respiratory tract）
and occasionally reaches the joint, causing exacerbation 
of arthritis.  This is partially substantiated by the 
findings that M. fermentans was detected within 
peripheral polymorphonuclear cells in 50％ of RA 
patients28.  This kind of phenomenon was described 
in reactive arthritis（ReA）associated with mostly 
enteric bacteria, such as Salmonella and Yersinia29，30. 
However, Henry et al. recently reported that Chlamydia 
as well as Mycoplasma could cause ReA in human 
TMJ16.  In either case the infection might result in 
the release of arthritogenic antigens, in transformation 
of immune reactivity by releasing proinflammatory 
cytokines.  Thus, it is possible that M. fermentans is 
carried inside the body by peripheral blood cells into the 
joints, as shown in the phenomenon described in ReA.
　As another interesting finding, we have shown that 
IgG antibodies present in SF of our patients have a high 
affinity to certain M. fermentans membrane lipopro-
teins, including p48 and p29.  p48 was recently shown 
to be an arthritogenic antigen to induce TNF- α
production from human monocytes31.  More interest-
ingly, various Mycoplasma species were shown to have 
affinity to cartilage, possibly promoting the homing of 
the bacteria to the joint tissue32.  In this regards, the 
fact that one of the M. fermentans derived lipoproteins, 
p29, was shown to mediate initial binding to some type 
of articular cells deserves special attention33.   It is also 
noteworthy that M. arthritidis was shown to share a 
common antigenic determinant with chondrocytes 
surface antigens or their products, glycosaminoglycans, 
suggesting molecular mimicry of mycoplasmal antigens 
in the pathogenesis of arthritis4.
　In conclusion, our findings suggest that M. fer- 
mentans infection was present in some TMD patients. 
We also first found that anti-M. fermentans Ab is 
produced locally in the TMJ, possibly reflecting 
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immunoreaction to this organism.  It is, however, still 
unknown how the bacteria can influence TMD, and 
further direct evidence is needed to determine the 
validity of this conjecture.
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